Skip to main content

Exelixis Pens Chemistry Deal with Elan Pharmaceuticals

NEW YORK, Aug 14 – Exelixis of South San Francisco, Calif., has announced an agreement with Elan Pharmaceuticals to develop a compound library, marking Exelixis’ initial chemistry deal.

“This is our first chemistry-focused collaboration and it validates the quality of the discovery organization, while offsetting some of the cost of building our large high throughput screening compound library for drug discovery at Exelixis,” George Scangos, Exelixis’s CEO, said in a statement released Monday.

Under the terms of the three-year deal with Elan, Exelixis said it would develop a small molecule library that would be available to both Elan and Exelixis.

Elan will provide Exelixis with an upfront payment and will make additional payments as compounds are made available. Further details were not disclosed.

Exelixis’ drug target capabilities combine model system genetics with the company’s screening platform, compound library, and chemistry capabilities.

The company, which has deals with Aventis, Bayer, Bristol-Myers Squibb, Protein Design Labs, Dow AgroSciences, is currently building an internal drug development program in oncology.

Exelixis has said it expects to identify its first compound by the end of 2001.


The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.